S
Sino Biological
Sino Biological is a specialist provider of protein, antibody and gene products
At a glance
- Status
- Listed
- Listing
- IPO 2021
- Outcome tier
- Thoroughbred$100M+ revenue
News
Open roles
Sino Biological in the Dongcheng District ecosystem
The Sino Biological office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
54 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Sino Biological was the backer or acquirer, 2022–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Sino Biological's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Sino Biological's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sino Biological on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sino Biological on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


